Jiangsu Recbio Technology Co (FRA:G93) Current Deferred Revenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:G93 Jiangsu Recbio Technology Co Ltd FRA:G93
24 GF Score
Price €0.50
! 6 Warning Signs
View Full Analysis

What is Jiangsu Recbio Technology Co Current Deferred Revenue?

Jiangsu Recbio Technology Co FRA:G93 -5.66% 24 Current Deferred Revenue is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Jiangsu Recbio Technology Co's current deferred revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

Jiangsu Recbio Technology Co Current Deferred Revenue Related Terms

Jiangsu Recbio Technology Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Jiangsu Recbio Technology Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Recbio Technology Co Current Deferred Revenue Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:G93
24GF Score
Jiangsu Recbio Technology Co Ltd FRA:G93
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
Jiangsu Recbio Technology Co (FRA:G93) has a Current Deferred Revenue of €0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jiangsu Recbio Technology Co and its competitors.
Is Jiangsu Recbio Technology Co's Current Deferred Revenue too high?
Jiangsu Recbio Technology Co's current Current Deferred Revenue is €0.00 Mil. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's Current Deferred Revenue compare to VRTX and REGN?
Jiangsu Recbio Technology Co's Current Deferred Revenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jiangsu Recbio Technology Co and its competitors. Jiangsu Recbio Technology Co's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current Current Deferred Revenue of €0.00 Mil. The current Current Deferred Revenue is €0.00 Mil. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current Current Deferred Revenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jiangsu Recbio Technology Co Business Description

Other Exchanges 02179:Hong Kong
Address No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score

Get the complete analysis for FRA:G93

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price